Creative Medical Technology Holdings, Inc. (CELZ)
NASDAQ: CELZ · IEX Real-Time Price · USD
4.575
+0.135 (3.04%)
At close: May 1, 2024, 12:20 PM
4.710
+0.135 (2.95%)
After-hours: May 1, 2024, 4:00 PM EDT
CELZ Revenue
In the year 2023, Creative Medical Technology Holdings had annual revenue of $9.00K, a decrease of -89.84%. Revenue in the quarter ending December 31, 2023 was $3.00K, a -83.87% decrease year-over-year.
Revenue (ttm)
$9.00K
Revenue Growth
-89.84%
P/S Ratio
689.62
Revenue / Employee
$2,250
Employees
4
Market Cap
6.21M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 9.00K | -79.60K | -89.84% |
Dec 31, 2022 | 88.60K | 846.00 | 0.96% |
Dec 31, 2021 | 87.75K | -76.75K | -46.65% |
Dec 31, 2020 | 164.50K | -1.00K | -0.60% |
Dec 31, 2019 | 165.50K | 41.10K | 33.04% |
Dec 31, 2018 | 124.40K | 119.60K | 2,491.67% |
Dec 31, 2017 | 4.80K | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Dec 31, 2007 | 0 | - | - |
Dec 31, 2006 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Healthcare Triangle | 33.20M |
Regional Health Properties | 17.16M |
Scorpius Holdings | 6.99M |
Trevena | 3.13M |
Predictive Oncology | 1.78M |
Soligenix | 839.36K |
CELZ News
- 5 weeks ago - Creative Medical Technology Holdings Provides Corporate Update - Business Wire
- 7 weeks ago - Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access - Business Wire
- 2 months ago - Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy - Business Wire
- 4 months ago - Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain - Accesswire
- 7 months ago - Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain - PRNewsWire
- 8 months ago - Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain - PRNewsWire
- 8 months ago - What Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth? - Accesswire
- 10 months ago - The Immunotherapy Market is Expected to Surpass $351.56 Billion by 2030 - Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is Contributing to this Growth - Accesswire